Anti-IL-11
Interleukin-11 signalling inhibition (anti-IL-11 antibody)
Written by Aaron CuhaReviewed Sep 2026
Also known as: IL-11 blockade, Anti-interleukin-11
Blocking a single inflammatory cytokine extended healthspan and lifespan in mice, and it worked when started in already old animals. No human ageing trial exists.
Overview
This is one of the more striking mouse results in recent ageing biology, and the detail that matters is when treatment started.
Interleukin-11 is a cytokine in the interleukin-6 family that rises with age and drives fibrosis and inflammatory signalling. A 2024 Nature paper reported that inhibiting IL-11 signalling extended both healthspan and lifespan in mice, with benefit when treatment began in animals that were already old.
Most lifespan interventions have to start young, which limits their usefulness to anybody already alive and ageing. An intervention that works late is a different proposition, which is why this result attracted the attention it did.
It is mouse data. No human ageing trial has been run, and anti-IL-11 antibodies are in early human development for fibrotic disease rather than for ageing.
Mechanism of action
Interleukin-11 signals through a receptor complex using IL-11RA and the shared gp130 subunit, activating JAK and STAT3 and also ERK signalling. It is a driver of fibroblast activation and fibrosis across organs, and its expression rises with age. Blocking it reduces pro-fibrotic and inflammatory signalling, and in the mouse work it also affected metabolic and mTOR-related pathways, which is one proposed route to the lifespan effect. Note that IL-11 has physiological roles including in haematopoiesis, so lifelong blockade is not consequence-free.
Human evidence
None for ageing. Anti-IL-11 agents are in early development for fibrotic disease, and no ageing or lifespan endpoint has been studied in people.
- No human trial has examined IL-11 inhibition for any ageing, healthspan or lifespan endpoint.
- Early human development targets fibrotic conditions, where IL-11's role is best established.
- Recombinant IL-11 was itself an approved drug for chemotherapy-induced thrombocytopenia, which means the physiological consequences of manipulating this cytokine in people are partly known and are not trivial.
- IL-11 has roles in haematopoiesis, so sustained blockade carries a plausible risk that has not been characterised over long periods.
What this does not tell you: Everything about the ageing claim is in mice. The late-start benefit is the most interesting part and also the part most in need of replication, because late-start lifespan results have a poor history of holding up across laboratories. Nothing here supports human use, and no anti-IL-11 product is available.
Reading the research record
This result is worth following for one specific reason. Almost every intervention that extends lifespan in mice has to begin early in life, which makes it scientifically interesting and practically useless for anyone already old. An intervention that works when started late is the category that could matter to a person, and this is one of the few claims in that category from a strong journal.
The appropriate scepticism is about replication rather than about plausibility. The Interventions Testing Program exists precisely because single-laboratory lifespan results, including late-start ones, frequently fail to reproduce at multiple sites, and the 2026 cohort documented compounds that worked at one dose and not another. Until IL-11 inhibition has been through something like that, treat it as the most promising untested idea rather than as an established one.
The evidence, charted
Fig. 1 · evidence composition
0of 1 citation (0%) is in people
Every citation cited here is Animal work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Every citation here was published in 2024.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Animal2024
Inhibition of IL-11 signalling extends mammalian healthspan and lifespan
Mouse work. Inhibiting interleukin-11 signalling extended both healthspan and lifespan, including when treatment began in already old animals. That late-start benefit is the feature that distinguishes it from most lifespan interventions, which must start early to work.
Nature
Frequently asked questions
Did blocking IL-11 really extend lifespan?
In mice, in a 2024 Nature paper, yes, including when treatment started in already old animals. There is no human ageing data and no multi-site replication of the lifespan result.
Why is the late start important?
Because most lifespan interventions in mice only work if started young, which makes them irrelevant to anyone already ageing. Something that works late is the only kind that could translate into a treatment rather than a lifelong regimen begun in youth.
Can I get an anti-IL-11 drug?
No. Nothing in this class is approved for any indication, and early human development is aimed at fibrotic disease rather than ageing.
Is blocking an inflammatory cytokine safe long term?
Unknown. IL-11 has physiological roles including in haematopoiesis, and recombinant IL-11 was itself once used as a drug to raise platelet counts. Sustained blockade in humans has not been characterised over long periods.